Recent News

• 05.09.2025 - Kymera Therapeutics Immunology Innovation Day/First Quarter 2025 Results Call
• 05.09.2025 - Kymera Therapeutics Immunology Innovation Day/First Quarter 2025 Results Call
• 04.24.2025 - Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
• 04.24.2025 - Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025
• 04.22.2025 - Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
• 04.22.2025 - Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
• 04.09.2025 - Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
• 04.09.2025 - Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
• 03.27.2025 - H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Recent Filings

• 04.09.2025 - 3 Initial statement of beneficial ownership of securities
• 04.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities